Oruka Therapeutics (NASDAQ:ORKA) Upgraded to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Oruka Therapeutics (NASDAQ:ORKA) to a strong-buy rating in a report released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($1.31) EPS, Q2 2026 earnings at ($1.46) EPS and FY2026 earnings at ($1.92) EPS.

A number of other research firms have also recently commented on ORKA. Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday. They issued an outperform rating and a $44.00 target price for the company. Wedbush initiated coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They issued an outperform rating and a $40.00 price objective for the company. Lifesci Capital initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an outperform rating and a $41.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a buy rating and a $40.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a buy rating for the company. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and a consensus target price of $41.25.

Oruka Therapeutics Trading Up 0.7 %

ORKA opened at $25.00 on Tuesday. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.